Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Job title: Medical Director, Mechanical Support Devices
NA Mark Estes III
Research Area(s) / Expertise:

Electrophysiology & Arrhythmia

 Job title: Professor of Medicine & Director
Dr NA Mark Estes III is an accomplished Professor of Medicine at the University of Pittsburgh and Director of the Clinical Cardiac Electrophysiology Fellows Program at the Heart and Vascular Institute at UPMC. He graduated from the University of Pennsylvania with an undergraduate degree and was elected to AOA at the University of Cincinnati College of Medicine. Dr. Estes completed his medical… View more
TCT Connect 2020: The Disrupt CAD III Trial
Author(s): Dean J Kereiakes Added: 3 years ago
Dr Dean J Kereiakes (The Lindner Research Center at The Christ Hospital, Cincinnati, OH, US) discusses the results of the Disrupt CAD III Trial. The study investigated the safety and effectiveness of the Shockwave Medical Coronary Intravascular Lithotripsy (IVL) System in de novo, calcified, stenotic coronary arteries prior to stenting. Questions 1. Why was the Disrupt CAD III study… View more

Intervention
The LAAOS III Study: Surgical AFIB Ablation Evaluation
Author(s): Richard Whitlock Added: 2 years ago
In this short late-breaking interview, Dr Richard Whitlock (McMaster University, CA) shares the key findings and lessons from the LAAOS III Surgical Atrial Fibrillation Ablation evaluation. The study showed that concomitant surgical AF ablation was not associated with a reduced risk of stroke, or systemic embolism at a mean follow-up of 3.8 years. Discussion points: Findings of LAAOS III study… View more

Electrophysiology & Arrhythmia
EuroPCR 23: FAME III Three-Year Follow-Up
Author(s): Frederik Zimmermann Added: 11 months ago
EuroPCR 23 – In this late-breaking science interview, we are joined by Prof Frederick Zimmermann (Catharina Hospital, NL) to discuss the findings from a 3-year follow-up of the FAME III trial. The objective of the FAME 3 trial was to demonstrate the noninferiority of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) compared to coronary artery bypass grafting (CABG)… View more

Vascular Disease and Surgery

Imaging & Diagnostics
ESC 2020: APOC-III Reduction in Cardiovascular Disease
Author(s): Jean-Claude Tardif Added: 3 years ago
Dr Jean-Claude Tardif (Montreal Heart Institute, Montreal, CA) discusses the effects of Apolipoprotein C-III (ApoC-III) reduction in cardiovascular (CV) disease. The administration of APOCIII-LRX in patients with hypertriglyceridemia and high CV risk was associated with inhibition of ApoC-III and lower levels of triglycerides. Questions: 1. What is the background of this study? 2. What was the… View more

Prevention & Chronic Conditions
EHRA 22: Results From the POWER-FAST III Trial
Author(s): Jose L Merino Added: 2 years ago
In this late-breaking interview filmed at EHRA 2022, Dr José Merino(Hospital Universitario La Paz, Madrid, Spain) discusses the findings of the POWER-FAST III trial, a study that aimed to compare atrial fibrillation ablation strategies of conventional radiofrequency ablation and high power radiofrequency ablation. Results suggest that PVA was achieved in both cohorts, with no significant… View more

Electrophysiology & Arrhythmia
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study
Author(s): Annapoorna Kini Added: 1 year ago
ACC.23/WCC — Principle investigator of YELLOW III, Dr Annapoorna Subhash Kini(Mount Sinai Hospital, US) joins us to talk about the study that assessed the effect of evolocumab (Repatha) on coronary plaque morphology using intravascular imaging and gene expression analysis of peripheral blood mononuclear cells (PBMC) in 140 patients with stable CAD on maximally tolerated statin therapy … View more

Imaging & Diagnostics

Prevention & Chronic Conditions
ACC 23: The STELLAR Phase II Trial: Sotatercept in Patients With Pulmonary Arterial Hypertension
Author(s): Marius Hoeper Added: 1 year ago
ACC.23/WCC— ProfMarius Hoeper (Hannover Medical School, DE) joins us to outline the findings of the late-breaking STELLAR phase III trial. The STELLAR Trial aims to study the safety and efficacy of sotatercept (MK-7962) and background pulmonary arterial hypertension (PAH) therapy in patients with PAH as compared to placebo. The investigators hypothesized that participants receiving sotatercept… View more

Prevention & Chronic Conditions